MD Biosciences nominated for Scottish Annual Life Sciences award: most promising new life sciences company.

Glasgow, Scotland – MD Biosciences has been nominated for the Scottish Enterprise Annual Life Sciences Award in the category of Most Promising New Life Science Company. MD Biosciences is one of three finalists in this category. Awards will be presented to recognize outstanding achievements of new life science companies during the Scottish Life Sciences Annual Dinner on February 9th in Edinburgh. The 2005 launch of the Inflammations Discovery Service along with cutting-edge mode of action platforms has positioned the company as a leading product and services provider for inflammations research. “Being nominated in this category is truly an honor and signifies the potential of our company, not only as seen by ourselves but also by our industry”, comments Dr. Eddie Moradian, Managing Director of MD Biosciences. This nomination also reflects MD Biosciences commitment and focus on the inflammations drug discovery market.

MD Biosciences provides researchers a unique combination of products and services. Investing time into customizing protocols to meet individual needs, along with learning and understanding clients’ objectives, hurdles and milestone requirements, enables MDB to contribute suggestions and alternatives to tackle the obstacles challenging the clients business. MDB maintains a unique position by providing flexibility in custom tailoring all procedures and offering the ability to use the same products for client’s research, allowing simultaneous in-house development while services are being out-sourced to MD Biosciences.

With laboratories and offices in Switzerland, Israel, and the United States as well as the MD Biosciences Inflammations Discovery Service in Scotland, the company has a unique team of scientists encompassing the globe and comprise inflammation specialists, pharmaco-biologists, in vitro laboratory personnel and project leaders, forming a network of contracted experts within areas of core competence.


————

The information in this press release should be considered accurate only as of the date of the release. MDB has no intention of updating and specifically disclaims any duty to update the information in these press releases.